Phase 3 Open-label Extension Trial With Rotigotine in Idiopathic Restless Legs Syndrome Subjects
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label trial to assess safety and tolerability of rotigotine in
subjects with idiopathic Restless Legs Syndrome (RLS), administered at an optimal dose for up
to 1 year in subjects who previously participated in SP790 (6-month pivotal trial) or SP794
(sleep lab trial). Subjects who successfully completed the Maintenance Period and the Taper
Period of SP790 or SP794 are allowed to enroll in this trial.